Personalized Antiplatelet Therapy to Prevent Recurrent Cardiovascular Events in After Ischemic Stroke
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1506 participants.
Also called NCT07943026
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 1,506 participants
- Sponsor
- Registry
-
NCT07943026 -
2025-523065-16-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Italy
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07943026. Randomized; single masking; primary purpose prevention. Start 2026-12 (anticipated); primary completion 2029-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Personalized Antiplatelet Therapy to Prevent Recurrent Cardiovascular Events in After Ischemic Stroke
- Acronym
- TAILOR
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Acetylsalicylic acid (ASA)/aspirin 100 mg daily
- Intervention (Drug)
- Clopidogrel 75 mg daily
- Intervention (Drug)
- Ticlopidine 250 mg twice daily
- Lead sponsor
- Azienda Usl di Bologna
Record details
- Record id
cardio:ct-nct07943026- Content hash
fd38d24ba523575063d1cff68a555ef0a0498dfe9270b04f35c737e4fda07082